CJC-1295 / Ipamorelin | Growth Hormone Research
AUD $130
For laboratory research use only. Not for human use.
Research-grade CJC-1295 and Ipamorelin blend — growth hormone secretagogues studied in preclinical models for growth hormone release, muscle recovery, and metabolic effects. Third-party HPLC tested to ≥98% purity. For laboratory research use only.
Supply Specifications
| Peptides | CJC-1295 (GHRH analogue) + Ipamorelin (GHRP) |
| Format | Lyophilised powder blend |
| Purity | ≥98% by HPLC (each component) |
| Testing | Third-party HPLC + Mass Spec |
| Storage | -20°C lyophilised |
| Use | Laboratory research use only |
| Price | AUD $130 |
Research Summary
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a DAC (Drug Affinity Complex) modification that extends its half-life. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. Together, they are studied for their synergistic effects on growth hormone release in preclinical models.
Preclinical research has examined the combination for apparent effects on body composition, muscle mass, and metabolic parameters. The two peptides act through complementary mechanisms — CJC-1295 via the GHRH receptor and Ipamorelin via the ghrelin receptor.
Neither CJC-1295 nor Ipamorelin is TGA-approved for human use in Australia. Available for laboratory research use only.
Related Research
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.